425 results
OT population excludes patients lost to follow-up, or that discontinued DTG for reasons of intolerance or toxicity. ITT = all patients that took at least 1 DTG tabletPrimary objective:* To evaluate the efficacy of DTG monotherapy in maintaining…
MK-1439 is a promising NNRTI to be used in combination with other antiretrovirals (ARTs) for the treatment of HIV infection. It is a potent inhibitor of HIV-1 replication in vitro and is active against both wild type virus and most common NNRTI…
To examine disease activity in patients with high serum adalimumab concentration who are randomly assigned to continuation of the regular dose or to dose interval prolongation and to examine the cost-effectiveness of this therapeutic drug monitoring…
The purpose of the study is to investigate the safety of LYC-30937 and to what extent LYC-30937 is tolerated. It will also investigate how quickly and to what extent LYC-30937 is absorbed and eliminated from the body (this is called pharmacokinetics…
The purpose of the study is to investigate how quickly and to what extent an injection under the skin (subcutaneous [sc]) of UCB4940 is absorbed and eliminated from the body (this is called pharmacokinetics) in comparison with the absorption and…
The objective of this study is to compare the efficacy of Infliximab-biosimilar to Infliximab-innovator and to demonstrate its noninferiority up to 30 weeks, in patients with ulcerative colitis or Crohn*s disease in remission under treatment with…
Period 1: The first objective, of period 1, is to compare the safety and efficacy of ABT-494 15 mg QD monotherapy, and 30 mg QD monotherapy versus weekly methotrexate (MTX) monotherapy for the treatment of signs and symptoms of rheumatoid arthritis…
To evaluate the efficacy and safety of a SCIT-treatment with a mutant recombinant fish-parvalbumin (mCyp c1) quantified in mass units and formulated in a solution with alum, in subjects with fish-allergy.
Period 1: The first objective, of period 1, is to compare the safety and efficacy of ABT-494 30 mg (QD) and 15 mg QD versus placebo on a background of csDMARD(s) for the treatment of signs and symptoms of rheumatoid arthritis (RA) in bDMARD-…
Period 1:The first objective, of period 1, is to compare the efficacy of ABT-494 15 mg QD and 30 mg QD versus placebo for the treatment of signs and symptoms of subjects with active RA who are on a stable dose of conventional synthetic disease-…
The primary objective of the research is to find out if treatment with BMS-931699 can improve systemic lupus erythematosus (SLE) disease activity. This will be measured by determining the proportion of BICLA responders who achieve BILAG disease…
To investigate whether an add-on mindset & physical therapy program based on the *Wim Hof Method* can safely and efficaciously be applied in patients with active axial spondyloarthritis.
The objective is to study the effectiveness of the online self management training Reuma Uitgedaagd! voor adults with a rheumatic disease.
Objective: To determine whether serum concentration guided dosing of infliximab is not inferior to standard dosing based on bodyweight in patients with severe sarcoidosis in terms of FVC change at 26 weeks.
To evaluate the efficacy of HDM-SPIRE in the reduction of symptoms and the use of allergy rescue medication associated with HDM allergy in subjects with clinically relevant symptoms.
The purpose of the study is to investigate how quickly and to what extent GP2017 is absorbed and eliminated from the body (this is called pharmacokinetics) after a single injection under the skin of the abdomen. This injection is administered by…
The purpose of the study is to investigate to what extent OMS721 is tolerated. This study will also investigate how quickly and to what extent OMS721 is absorbed and eliminated from the body (this is called pharmacokinetics). In addition, this study…
The purpose of the study is to investigate to what extent RO5459072 is safe and well tolerated.It will also be investigated how quickly and to what extent RO5459072 is absorbed, distributed to and removed from the body (this is called…
The primary objectives of this study are to assess whether 80 mg ixekizumab every 2 weeks (Q2W) is:• noninferior to ustekinumab at Week 12 in the treatment of patients with moderate-to-severe plaque psoriasis as measured by proportion of patients…
Our primary objective is to investigate the effects of endotoxin-induced systemic inflammation and subsequent development of endotoxin tolerance on the inflammatory response following Fluenz® administration in vivo. To evaluate whether these effects…